{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:05:35Z","timestamp":1784311535277,"version":"3.55.0"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Breast cancer has been categorized into molecular subtypes using immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH) since the early 2000s. However, recent research suggests that gene expression testing, specifically Prosigna\u00ae Prediction Analysis of Microarray 50 (PAM50), provides more accurate classification methods. In this retrospective study, we compared the results of IHC\/FISH and PAM50 testing. We also examined the impact of various PAM50 parameters on overall survival (OS) and progression-free survival (PFS). Results: We analyzed 42 unilateral breast cancer samples, with 18 classified as luminal A, 10 as luminal B, 8 as Human epidermal growth factor receptor 2 (HER2)-positive, and 6 as basal-like using PAM50. Interestingly, 17 out of the 42 samples (40.47%) showed discordant results between histopathological assessment and the PAM50 classifier. While routine IHC\/FISH resulted in classification differences for a quarter to a third of samples within each subtype, all basal-like tumors were misclassified. Hormone receptor-positive tumors (hazard rate: 8.7803; p = 0.0085) and patients who had higher 10-year recurrence risk scores (hazard rate: 1.0539; p = 0.0201) had shorter OS and PFS. Conclusions: Our study supports the existing understanding of molecular subtypes in breast cancer and emphasizes the overlap between clinical characteristics and molecular subtyping. These findings underscore the value of gene expression profiling, such as PAM50, in improving treatment decisions for breast cancer patients.<\/jats:p>","DOI":"10.3390\/genes14091708","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:45:42Z","timestamp":1693194342000},"page":"1708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-3624","authenticated-orcid":false,"given":"Magdolna","family":"Dank","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorottya","family":"M\u00fchl","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annam\u00e1ria","family":"P\u00f6lh\u00f6s","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Csanda","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-6343","authenticated-orcid":false,"given":"Magdolna","family":"Herold","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"},{"name":"Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila Kristof","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Madaras","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Kulka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timea","family":"Palhazy","sequence":"additional","affiliation":[{"name":"Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, H-1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Tokes","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Radiology, Semmelweis University, H-1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-563X","authenticated-orcid":false,"given":"Mihaly","family":"Ujhelyi","sequence":"additional","affiliation":[{"name":"TritonLife Medical Center, H-1135 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-4196","authenticated-orcid":false,"given":"Attila Marcell","family":"Szasz","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-4889","authenticated-orcid":false,"given":"Zoltan","family":"Herold","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, May 10). Breast Cancer, Available online: https:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/breast-cancer\/en\/."},{"key":"ref_2","unstructured":"American Cancer Society (2023, May 10). Breast Cancer Facts & Figures 2021\u20132022. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2021-2022.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","first-page":"317","article-title":"Heterogeneity in hormone receptor status in primary and metastatic breast cancer","volume":"12","author":"Osborne","year":"1985","journal-title":"Semin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2014Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000351193","article-title":"St. Gallen 2013: Brief preliminary summary of the consensus discussion","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000430488","article-title":"St. Gallen\/Vienna 2015: A Brief Summary of the Consensus Discussion","volume":"10","author":"Gnant","year":"2015","journal-title":"Breast Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Dai","year":"2002","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-012-2143-0","article-title":"PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer","volume":"135","author":"Prat","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-12-0286","article-title":"A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen","volume":"18","author":"Chia","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., and Snider, J. (2015). Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genom., 8.","DOI":"10.1186\/s12920-015-0129-6"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1185\/03007995.2015.1037730","article-title":"Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer","volume":"31","author":"Martin","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1158\/1078-0432.CCR-20-4102","article-title":"Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy","volume":"27","author":"Pascual","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","article-title":"Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score","volume":"33","author":"Sestak","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41391-021-00325-4","article-title":"A comparative study of PCS and PAM50 prostate cancer classification schemes","volume":"24","author":"Yoon","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-21-4289","article-title":"Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Coleman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/bcr1649","article-title":"Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers","volume":"9","author":"Jumppanen","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_25","first-page":"301","article-title":"Pathological diagnosis, work-up and reporting of breast cancer. Recommendations from the 4th Breast Cancer Consensus Conference","volume":"64","author":"Cserni","year":"2020","journal-title":"Magy. Onkol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/0284186X.2017.1403044","article-title":"The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes","volume":"57","author":"Laenkholm","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41379-020-0643-8","article-title":"Prosigna(R) breast cancer assay: Histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK) index for breast cancer prognosis","volume":"34","author":"Baskota","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., and Storhoff, J. (2014). Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-177"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","article-title":"Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up","volume":"19","author":"Ohnstad","year":"2017","journal-title":"Breast Cancer Res."},{"key":"ref_34","unstructured":"Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer International Publishing. [8th ed.]."},{"key":"ref_35","first-page":"348","article-title":"Systemic treatment of breast cancer: Professional guideline","volume":"64","author":"Horvath","year":"2020","journal-title":"Magy. Onkol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-023-06886-3","article-title":"Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer","volume":"199","author":"Phakathi","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bastien, R.R., Rodriguez-Lescure, A., Ebbert, M.T., Prat, A., Munarriz, B., Rowe, L., Miller, P., Ruiz-Borrego, M., Anderson, D., and Lyons, B. (2012). PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med. Genom., 5.","DOI":"10.1186\/1755-8794-5-44"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Erber, R., Angeloni, M., Stohr, R., Lux, M.P., Ulbrich-Gebauer, D., Pelz, E., Bankfalvi, A., Schmid, K.W., Walter, R.F.H., and Vetter, M. (2022). Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-like Subtyping by Tumor Grade\/Immunohistochemistry and Influence on Oncologist\u2019s Decision on Systemic Therapy in a Real-World Setting. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158716"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1093\/annonc\/mds586","article-title":"Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 Working Group Statement","volume":"23","author":"Guiu","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17440","article-title":"Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: A systematic review and cost-effectiveness analysis","volume":"17","author":"Ward","year":"2013","journal-title":"Health Technol. Assess."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102496","DOI":"10.1016\/j.ctrv.2022.102496","article-title":"Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer","volume":"112","author":"Falato","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000439135","article-title":"BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters","volume":"83","author":"Madaras","year":"2016","journal-title":"Pathobiology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kj\u00e4llquist, U., Acs, B., Margolin, S., Karlsson, E., Kessler, L.E., Garcia Hernandez, S., Ekholm, M., Lundgren, C., Olsson, E., and Lindman, H. (2022). Real World Evaluation of the Prosigna\/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. Cancers, 14.","DOI":"10.3390\/cancers14112615"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","article-title":"PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer","volume":"36","author":"Laenkholm","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hequet, D., Callens, C., Gentien, D., Albaud, B., Mouret-Reynier, M.A., Dubot, C., Cottu, P., Huchon, C., Zilberman, S., and Berseneff, H. (2017). Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(R) Test in the management of early-stage breast cancers. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185753"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e12527","DOI":"10.1200\/JCO.2022.40.16_suppl.e12527","article-title":"The use of clinical impact of the breast cancer intrinsic subtype-Prosigna assay for adjuvant treatment decision in early breast cancer with hormone receptor positive and HER-2 negative Middle East women","volume":"40","author":"Zidan","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/9\/1708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:39Z","timestamp":1760128839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/9\/1708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["genes14091708"],"URL":"https:\/\/doi.org\/10.3390\/genes14091708","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}